FDA Grants Orphan Drug Designation for Lundbeck's Cushing's Syndrome Drug

The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for asedebart (Lu AG13909), Lundbeck's novel investigational anti-ACTH monoclonal antibody. The designation is for the treatment of endogenous Cushing's syndrome.

Endogenous Cushing's syndrome is a rare endocrine disorder, most commonly driven by excessive cortisol production. This condition can lead to significant health problems, including obesity, high blood pressure, diabetes, and cardiovascular disease.

Orphan Drug Designation is granted to therapies intended to treat rare diseases or conditions. This status provides incentives to encourage the development of new treatments for such conditions.

Lundbeck, a pharmaceutical company focused on treatments for central nervous system disorders, is developing asedebart. The antibody targets ACTH, a hormone that stimulates the adrenal glands to produce cortisol. The aim of the drug is to reduce the overproduction of this hormone.